Richard A. Heyman Sells 518 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard A. Heyman sold 518 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $27.54, for a total transaction of $14,265.72. Following the sale, the director now directly owns 128,585 shares of the company’s stock, valued at $3,541,230.90. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Enliven Therapeutics Stock Performance

Shares of NASDAQ:ELVN opened at $27.53 on Friday. Enliven Therapeutics, Inc. has a 1-year low of $9.80 and a 1-year high of $27.67. The company’s fifty day moving average is $23.21 and its two-hundred day moving average is $21.97. The stock has a market capitalization of $1.29 billion, a price-to-earnings ratio of -14.26 and a beta of 1.09.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.17. Sell-side analysts expect that Enliven Therapeutics, Inc. will post -1.98 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ELVN. SG Americas Securities LLC acquired a new stake in shares of Enliven Therapeutics in the third quarter valued at approximately $256,000. The Manufacturers Life Insurance Company acquired a new stake in Enliven Therapeutics in the 2nd quarter valued at approximately $322,000. Marshall Wace LLP acquired a new stake in Enliven Therapeutics in the 2nd quarter valued at approximately $4,489,000. First Turn Management LLC bought a new stake in Enliven Therapeutics during the 2nd quarter valued at $9,657,000. Finally, Nicholas Investment Partners LP acquired a new position in Enliven Therapeutics during the 2nd quarter worth $1,310,000. 95.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have weighed in on ELVN shares. Robert W. Baird initiated coverage on shares of Enliven Therapeutics in a report on Tuesday, June 11th. They set an “outperform” rating and a $32.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $37.00 price objective on shares of Enliven Therapeutics in a report on Tuesday. Finally, Baird R W raised Enliven Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.